The FDA approved ISEMBYLD for spinal muscular atrophy in adults and children receiving an SMN2-targeted treatment. Scholar Rock said it will conduct a pregnancy safety study and submit fracture alerts requested by the FDA, correcting management’s earlier statement that no post-approval safety commitments applied.
Key Highlights
- Management corrected an erroneous statement made during the September 14, 2026, investor call.
- The FDA requires Scholar Rock to establish a pregnancy safety study for ISEMBYLD.
- The company must submit serious and non-serious fracture cases from domestic and foreign sources as alert reports.
Scholar Rock Holding Corp (NASDAQ: SRRK) said ISEMBYLD has received FDA approval for spinal muscular atrophy treatment in adults and children receiving an SMN2-targeted therapy. The approval carries safety-related obligations that management had incorrectly described during the company’s September 14, 2026, investor call.
ISEMBYLD Approval Includes Safety Commitments
The FDA requires Scholar Rock to create a pregnancy safety study focused on complications and birth outcomes involving exposed pregnancies. The regulator also requested reporting of serious and non-serious fracture cases from domestic and foreign sources. Those cases must be submitted as alert reports. The requirements apply in connection with ISEMBYLD’s approval. During the question-and-answer portion of the investor call, management had stated that the FDA did not require post-approval commitments related to bone or reproductive safety.
Scholar Rock Plans Required Follow-Up
Scholar Rock said it intends to conduct the pregnancy study and submit the requested fracture reports. The study will collect and assess information on pregnancy complications and birth outcomes. The fracture reporting obligation covers cases identified domestically and internationally. The company’s disclosure was signed on September 15, 2026, by Junlin Ho, general counsel and corporate secretary.
FAQs
Q: What safety study does the FDA require for Scholar Rock’s ISEMBYLD?
A: The FDA requires Scholar Rock to establish a pregnancy safety study for ISEMBYLD. The study will examine pregnancy complications and birth outcomes involving exposed pregnancies.
Q: What fracture reports must Scholar Rock submit for ISEMBYLD?
A: The FDA requested reporting of serious and non-serious fracture cases identified from domestic and foreign sources. Scholar Rock must submit those cases as alert reports in connection with ISEMBYLD’s approval.
Q: When did Scholar Rock correct its ISEMBYLD safety statement?
A: Scholar Rock corrected the statement in its disclosure signed on September 15, 2026. Management had made the incorrect statement during the September 14, 2026, investor call.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.